Sickle Cell Disease - Stroke Prevention in Nigeria Trial
Status:
Completed
Trial end date:
2019-01-31
Target enrollment:
Participant gender:
Summary
Given large absolute numbers of individuals with sickle cell disease in Nigeria, hydroxyurea
therapy for all individuals with sickle cell disease may not be initially feasible; however,
a targeted strategy of hydroxyurea use for primary prevention of strokes is an alternative to
the standard therapy (observation) for high-risk individuals. The investigators propose a
feasibility study, Sickle Cell Disease - Stroke Prevention in Nigeria (SPIN) Trial, to
determine whether hydroxyurea can be used for primary prevention of strokes in Nigerian
children with sickle cell anemia.
Phase:
N/A
Details
Lead Sponsor:
Vanderbilt University Vanderbilt University Medical Center
Collaborators:
Aminu Kano Teaching Hospital Barau Dikko Teaching Hospital/Kaduna State University National Institute of Neurological Disorders and Stroke (NINDS) National Institutes of Health (NIH)